135 related articles for article (PubMed ID: 7720242)
21. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
22. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
23. Multiplexing determination of small cell lung cancer biomarkers and their isovariants in serum by immunocapture LC-MS/MS.
Torsetnes SB; Levernæs MS; Broughton MN; Paus E; Halvorsen TG; Reubsaet L
Anal Chem; 2014 Jul; 86(14):6983-92. PubMed ID: 24945626
[TBL] [Abstract][Full Text] [Related]
24. Characteristics and clinical validity of two immunoassays for ProGRP.
Nordlund MS; Stieber P; Brustugun OT; Warren DJ; Paus E
Tumour Biol; 2012 Aug; 33(4):1105-13. PubMed ID: 22399443
[TBL] [Abstract][Full Text] [Related]
25. Elevated progastrin-releasing peptide(31-98) concentrations in pleural effusions due to small-cell lung carcinoma.
Shijubo N; Hirasawa M; Sasaki H; Igarashi T; Fujita A; Kodama T; Yamaguchi K; Abe S
Respiration; 1996; 63(2):106-10. PubMed ID: 8966363
[TBL] [Abstract][Full Text] [Related]
26. Digging deeper into the field of the small cell lung cancer tumor marker ProGRP: a method for differentiation of its isoforms.
Torsetnes SB; Nordlund MS; Paus E; Halvorsen TG; Reubsaet L
J Proteome Res; 2013 Jan; 12(1):412-20. PubMed ID: 23190087
[TBL] [Abstract][Full Text] [Related]
27. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
28. Stability of pro-gastrin-releasing peptide in serum versus plasma.
Yoshimura T; Fujita K; Kawakami S; Takeda K; Chan S; Beligere G; Dowell B
Tumour Biol; 2008; 29(4):224-30. PubMed ID: 18781094
[TBL] [Abstract][Full Text] [Related]
29. Determining ProGRP and isoforms in lung and thyroid cancer patient samples: comparing an MS method with a routine clinical immunoassay.
Torsetnes SB; Broughton MN; Paus E; Halvorsen TG; Reubsaet L
Anal Bioanal Chem; 2014 Apr; 406(11):2733-8. PubMed ID: 24518900
[TBL] [Abstract][Full Text] [Related]
30. Production and Characterization of Monoclonal Antibodies for Immunoassay of the Lung Cancer Marker proGRP.
Nordlund MS; Fermer C; Nilsson O; Warren DJ; Paus E
Tumour Biol; 2007; 28(2):100-10. PubMed ID: 17287611
[TBL] [Abstract][Full Text] [Related]
31. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin-releasing peptide levels.
Goto K; Kodama T; Hojo F; Kubota K; Kakinuma R; Matsumoto T; Ohmatsu H; Sekine I; Nagai K; Nishiwaki Y
Cancer; 1998 Mar; 82(6):1056-61. PubMed ID: 9506349
[TBL] [Abstract][Full Text] [Related]
33. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
[TBL] [Abstract][Full Text] [Related]
34. Automated time-resolved immunofluorometric assay for progastrin-releasing peptide.
Nordlund MS; Warren DJ; Nustad K; Bjerner J; Paus E
Clin Chem; 2008 May; 54(5):919-22. PubMed ID: 18443179
[TBL] [Abstract][Full Text] [Related]
35. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
[TBL] [Abstract][Full Text] [Related]
36. Elevated plasma concentrations of C-flanking gastrin-releasing peptide in small-cell lung cancer.
Holst JJ; Hansen M; Bork E; Schwartz TW
J Clin Oncol; 1989 Dec; 7(12):1831-8. PubMed ID: 2555450
[TBL] [Abstract][Full Text] [Related]
37. Serum progastrin-releasing peptide levels followed by whole-body positron emission tomography detects early recurrence of small-cell lung cancer.
Yamaguchi H; Soda H; Kitazaki T; Nakano H; Fujino S; Nakamura Y; Kohno S
Respirology; 2007 Jan; 12(1):137-9. PubMed ID: 17207039
[TBL] [Abstract][Full Text] [Related]
38. CYFRA 21-1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients.
Nakahama H; Tanaka Y; Fujita Y; Fujii M; Sugita M
Respirology; 1998 Sep; 3(3):207-10. PubMed ID: 9767622
[TBL] [Abstract][Full Text] [Related]
39. High Sensitive Immunoelectrochemical Measurement of Lung Cancer Tumor Marker ProGRP Based on TiO₂-Au Nanocomposite.
Wei Z; Cai X; Zhang J; Fan J; Xu J; Xu L
Molecules; 2019 Feb; 24(4):. PubMed ID: 30781735
[TBL] [Abstract][Full Text] [Related]
40. Serum pro-gastrin-releasing peptide (31-98) in benign prostatic hyperplasia and prostatic carcinoma.
Nagakawa O; Furuya Y; Fujiuchi Y; Fuse H
Urology; 2002 Sep; 60(3):527-30. PubMed ID: 12350511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
